Last reviewed · How we verify
MET + Glibenclamide Group
This combination of metformin and glibenclamide reduces blood glucose by improving insulin sensitivity and stimulating pancreatic insulin secretion.
This combination of metformin and glibenclamide reduces blood glucose by improving insulin sensitivity and stimulating pancreatic insulin secretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | MET + Glibenclamide Group |
|---|---|
| Also known as | Daonil®, Glucophage |
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Drug class | Antidiabetic combination (biguanide + sulfonylurea) |
| Target | AMPK pathway (metformin); ATP-sensitive potassium channel (glibenclamide) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity through AMPK activation and mitochondrial effects. Glibenclamide is a sulfonylurea that stimulates insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta cells. Together, they provide complementary glucose-lowering effects through different mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Lactic acidosis
- Weight gain
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |